stockrow
Saturday 7 November 2026
Export EPRX’s income statement to Excel — free account
Eupraxia Pharmaceuticals Inc.
EPRX Healthcare Biotechnology
- EPS
- +11.5%
- Free cash flow
- −56.4%
Quarter to June 2026, against a year earlier
6.83
0.23
+3.48%
Follow EPRX
Alert me
Eupraxia Pharmaceuticals Inc. (EPRX) P/E ratio
Eupraxia Pharmaceuticals Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MNPR Monopar Therapeutics Inc. compare | n/m |
| STTK Shattuck Labs, Inc. compare | n/m |
| GYRE Gyre Therapeutics, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| OCS Oculis Holding AG compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. | n/m |
| ARVN Arvinas, Inc. compare | n/m |
| CRMD CorMedix Inc compare | 2.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)